Esperion Therapeutics (ESPR) News Today $1.82 -0.03 (-1.35%) Closing price 03:59 PM EasternExtended Trading$1.83 +0.01 (+0.27%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest UpdateEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 31,240,000 shares, a decrease of 8.1% from the January 15th total of 33,980,000 shares. Currently, 16.0% of the shares of the company are sold short. Based on an average trading volume of 6,230,000 shares, the days-to-cover ratio is presently 5.0 days.February 18 at 10:41 PM | marketbeat.comEsperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4February 18 at 8:00 AM | globenewswire.comEsperion Therapeutics (ESPR) Expected to Announce Earnings on TuesdayEsperion Therapeutics (NASDAQ:ESPR) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18 at 5:16 AM | marketbeat.comZacks Research Issues Negative Outlook for ESPR EarningsFebruary 18 at 2:05 AM | americanbankingnews.comZacks Research Has Negative Forecast for ESPR Q3 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, February 12th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical cFebruary 17, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Given Market Outperform Rating at JMP SecuritiesFebruary 14, 2025 | americanbankingnews.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 13, 2025 | globenewswire.comEsperion Therapeutics' (ESPR) Market Outperform Rating Reaffirmed at JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday.February 11, 2025 | marketbeat.comEsperion price target lowered to $4 from $7 at JMP SecuritiesFebruary 11, 2025 | markets.businessinsider.comEsperion stock target cut to $4 by JMP SecuritiesFebruary 11, 2025 | msn.comEsperion stock holds Buy rating, $16 target from H.C. WainwrightFebruary 11, 2025 | msn.comEsperion Therapeutics' (ESPR) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday.February 11, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from BrokeragesFebruary 11, 2025 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from AnalystsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a holFebruary 6, 2025 | marketbeat.comEsperion (ESPR) Receives a Sell from Bank of America SecuritiesFebruary 4, 2025 | markets.businessinsider.comWhat is HC Wainwright's Estimate for ESPR FY2028 Earnings?Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at HC Wainwright cut their FY2028 EPS estimates for Esperion Therapeutics in a report released on Thursday, January 23rd. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn $0.16January 27, 2025 | marketbeat.comCautious Outlook on Esperion: Sell Rating Amid Market Challenges for Bempedoic AcidJanuary 23, 2025 | markets.businessinsider.comPromising Potential of Esperion’s Non-Statin Drugs in Cardiovascular Disease ManagementJanuary 23, 2025 | markets.businessinsider.comJMP Securities maintains $7 target on Esperion stockJanuary 23, 2025 | msn.comEsperion Therapeutics' (ESPR) "Market Outperform" Rating Reiterated at JMP SecuritiesJMP Securities reissued a "market outperform" rating and set a $7.00 price objective on shares of Esperion Therapeutics in a research report on Thursday.January 23, 2025 | marketbeat.comEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Thursday.January 23, 2025 | marketbeat.comBuy Rating for Esperion Based on Strong Clinical Data and Market Adoption of NEXLETOL and NEXLIZETJanuary 23, 2025 | markets.businessinsider.comCantor Fitzgerald Estimates ESPR FY2025 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Esperion Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earJanuary 23, 2025 | marketbeat.comResearch Analysts Set Expectations for ESPR FY2025 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Esperion Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will earn $0.05 per shaJanuary 22, 2025 | marketbeat.comEsperion Therapeutics CFO sells shares worth $20January 21, 2025 | msn.comEsperion Therapeutics chief commercial officer sells $277 in stockJanuary 21, 2025 | msn.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Position Lifted by Barclays PLCBarclays PLC lifted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 99.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 309,671 shares of the biopharJanuary 18, 2025 | marketbeat.comBank of America Securities Reaffirms Their Sell Rating on Esperion (ESPR)January 16, 2025 | markets.businessinsider.comEsperion stock falls on higher operating expense forecastJanuary 16, 2025 | msn.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Hold" from BrokeragesShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommenJanuary 12, 2025 | marketbeat.comEsperion’s Strategic International Expansion and Revenue Growth Justify Buy RatingJanuary 10, 2025 | markets.businessinsider.com3 Small-Cap Healthcare Stocks With Big Upside PotentialJanuary 9, 2025 | stocknews.comEsperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | markets.businessinsider.com3 Healthcare Innovators with Analyst-Endorsed UpsideDecember 26, 2024 | stocknews.comPublic Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Public Employees Retirement System of Ohio purchased a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 367,373 shares of the biopharmaceutical company's stock,December 21, 2024 | marketbeat.comWellington Management Group LLP Acquires 241,512 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wellington Management Group LLP boosted its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 66.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 602,936 shares of the biopharmaceutical company's stockDecember 20, 2024 | marketbeat.com3 High-Growth Biotech Stocks to WatchDecember 19, 2024 | stocknews.comPaul Choi Assigns Hold Rating to Esperion Due to Market Uncertainty and Pipeline ChallengesDecember 19, 2024 | markets.businessinsider.comAnalysts Offer Predictions for ESPR FY2024 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will earnDecember 19, 2024 | marketbeat.comEsperion closes refinancing transactionsDecember 19, 2024 | markets.businessinsider.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the four research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and three hDecember 18, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at The Goldman Sachs GroupThe Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday. They set a "neutral" rating and a $4.00 price objective for the company.December 18, 2024 | marketbeat.comEsperion Strengthens Balance Sheet with Closing of Significant Refinancing TransactionsDecember 18, 2024 | globenewswire.comCantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight RecommendationDecember 17, 2024 | msn.comEsperion initiated with an Overweight at Cantor FitzgeraldDecember 17, 2024 | markets.businessinsider.comEsperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Cantor FitzgeraldCantor Fitzgerald initiated coverage on Esperion Therapeutics in a report on Tuesday. They set an "overweight" rating and a $8.00 price objective on the stock.December 17, 2024 | marketbeat.comEsperion’s Strategic Debt Refinancing Boosts Financial Stability and Investor AppealDecember 15, 2024 | markets.businessinsider.comEsperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday.December 13, 2024 | marketbeat.comEsperion Announces $210 Million Convertible Debt FinancingDecember 13, 2024 | globenewswire.comEsperion’s Strategic Expansion and International Growth Justify Buy RatingDecember 12, 2024 | markets.businessinsider.com Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼-0.310.60▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼94▲ESPR Articles Average Week Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kiniksa Pharmaceuticals News Today Dyne Therapeutics News Today Structure Therapeutics News Today Ardelyx News Today Indivior News Today Nurix Therapeutics News Today Vir Biotechnology News Today Syndax Pharmaceuticals News Today Arvinas News Today ANI Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESPR Stock Alerts